

Risk Factors Traced for Postpolypectomy Bleeding

BY DENISE NAPOLI
Assistant Editor

WASHINGTON — Large polyp size and the use of anticoagulants raised the risk of delayed postpolypectomy hemorrhage, but aspirin and a history of hypertension did not, according to a study presented at the annual Digestive Disease Week.

The results stand in contrast to studies finding that hypertension, polyp location, and sessile (as opposed to pedunculated) polyps were risk factors for delayed bleeding, wrote Dr. Nadim Salfiti and associates at the University of Minnesota, Minneapolis.

In the case-control, retrospective chart review, the researchers analyzed 41 cases of postpolypectomy bleeding and 132 control cases at the Minneapolis VA Medical Center in 1999-2006. Mean age of the 41 case patients was 64 years, all were male, and most were white. Inclusion criteria for cases were delayed hematochezia occurring 6 hours to 14 days after polyp resection, and one of the following: hospital admission, blood transfusion, drop

in hemoglobin of more than 1 g/dL, or repeat colonoscopy.

The mean polyp size was 10.5 mm for cases and 6.7 mm for controls, a significant difference; 37% of cases and 11% of controls had a polyp size greater than 1 cm. Heparin or warfarin were used within 1 week after polypectomy in 34% of the patients with hemorrhage, a rate significantly higher than the 9% rate among controls.

At least one dose of aspirin was admin-

istered to roughly 40% of both cases and controls within the time period from 1 week before to 1 week after polypectomy, and slightly more than 60% of both cases and controls were hypertensive. Diabetes and lung disease were moderately significant risk factors, and coronary artery disease was present in 59% of cases and 32% of controls, a significant difference.

"This is the first study evaluating the risk of [using] anticoagulant medications after polypectomy," Dr. Salfiti noted in an

interview. "These results ... provide some information that could facilitate the decision regarding the timing of resuming anticoagulation."

Dr. Salfiti cautioned, however, that "each patient should be evaluated individually, and the risks of postpolypectomy bleeding versus the risk of some form of thromboembolic event in the short-term need to be assessed to decide how long anticoagulation should be delayed, if at all." ■

Continued from previous page

Those with complicated diverticulitis and an abscess requiring percutaneous drainage should be advised to undergo colectomy because severe recurrent sepsis occurs in 41% of such patients.

Urgent sigmoid colectomy is necessary in patients with diffuse peritonitis and those who fail nonsurgical management for acute diverticulitis.

After resolution of an initial episode of acute diverticulitis, colonoscopy or contrast enema x-ray should be performed to confirm the diagnosis and to exclude other diagnoses, primarily cancer, ischemia, and inflammatory bowel disease.

Long-term fiber supplementation after an initial attack of acute diverticulitis may prevent recurrence in more than 70% of patients for at least 5 years.

Whether to recommend elective sigmoid colectomy after recovery from an acute episode of acute diverticulitis should be an individual decision. Roughly one-third of patients with an initial attack will have a second; after a second attack, a further one-third will have another attack. Patients who have a severe initial attack, especially if treated nonoperatively, and those in whom carcinoma cannot be excluded have stronger indications for elective colectomy.

Laparoscopic colectomy is appropriate in selected patients with diverticular disease; in experienced hands, it carries no increased risk of complications or cost. Pain and recovery time are potentially less with laparoscopic colectomy than with open laparotomy. ■

Reference

J. Rafferty, P. Shellito, N.H. Hyman, W.D. Buie, and the Standards Committee of the American Society of Colon and Rectal Surgeons. Practice parameters for sigmoid diverticulitis. *Dis. Colon Rectum* 2006;49:939-44.

Are her symptoms
more *typical*
than *atypical*?

©2006 Astellas Pharma US, Inc. AD550001-MK 11/06 Printed in USA

Although chest pain is the most common symptom of myocardial infarction among both sexes,¹ women often present with symptoms that are not typically seen in men.² Coronary heart disease can be different in women, and many challenges exist in risk stratification and decision making.^{3,4}

Myocardial perfusion imaging (MPI) can provide important risk stratification information in women.⁴ Approximately 40% of women referred for MPI are candidates for pharmacologic stress.³ For those unable to exercise adequately, Adenoscan stress provides interpretable MPI results in 98.7% of patients.⁵

COMMITTED TO HER HEART®

IMPORTANT SAFETY INFORMATION

Intravenous Adenoscan® (adenosine injection) is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

Approximately 2.6% and 0.8% of patients developed second- and third-degree AV block, respectively. All episodes of AV block have been asymptomatic, transient, and did not require intervention; less than 1% required termination of adenosine infusion.

Fatal cardiac arrest, sustained ventricular tachycardia (requiring resuscitation), and non-fatal myocardial infarction have been reported coincident with Adenoscan infusion. Patients with unstable angina may be at greater risk.

Side effects that were seen most often included flushing (44%), chest discomfort (40%), and dyspnea (28%). Side effects usually resolve quickly when infusion is terminated and generally do not interfere with test results.

Despite adenosine's short half-life, 10.6% of the side effects started several hours after the infusion terminated, and 8.4% of the side effects that began during the infusion persisted for up to 24 hours after infusion. In many cases, it is not possible to know whether these late adverse events are the result of Adenoscan infusion.

Please see brief summary of prescribing information on the next page.

1. Isaac D, et al. *Can J Cardiol*. 2001;17(suppl D):38D-48D. 2. Wenger NK. *Cardiovasc Res*. 2002;53:558-567. 3. Mieres JH, et al. *J Nucl Cardiol*. 2003;10:95-101. 4. Hachamovitch R, et al. *J Am Coll Cardiol*. 1996;28:34-44. 5. Cerqueira MD, et al. *J Am Coll Cardiol*. 1994;23:384-389.

ADENOSCAN®
adenosine injection

astellas

Astellas Pharma US, Inc.